AR044782A1 - Espirobenzazepinas sustituidas utiles como antagonistas de los receptores de vasopresina - Google Patents

Espirobenzazepinas sustituidas utiles como antagonistas de los receptores de vasopresina

Info

Publication number
AR044782A1
AR044782A1 ARP040102087A ARP040102087A AR044782A1 AR 044782 A1 AR044782 A1 AR 044782A1 AR P040102087 A ARP040102087 A AR P040102087A AR P040102087 A ARP040102087 A AR P040102087A AR 044782 A1 AR044782 A1 AR 044782A1
Authority
AR
Argentina
Prior art keywords
formula
antagonists
useful
receptors
hyponatremia
Prior art date
Application number
ARP040102087A
Other languages
English (en)
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of AR044782A1 publication Critical patent/AR044782A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a benzazepinas sustituidas no péptidas de la fórmula (1), las cuales son útiles como antagonistas de los receptores de vasopresina para tratar afecciones asociadas con la actividad de los receptores de vasopresina tal como aquellas que involucran la resistencia vascular incrementada y la insuficiencia cardíaca, incluyendo la disfunción cardíaca congestiva, hiponatremia e hipertensión, entre otras descritas. Las composiciones farmacéuticas que comprenden un compuesto de fórmula (1) y los métodos para tratar afecciones tales como hipertensión, disfunción cardíaca congestiva, insuficiencia cardíaca, vasospasmo coronario, isquemia cardíaca, cirrosis hepática, hiponatremia, vasospasmo renal, insuficiencia renal, nefropatía diabética, edema cerebral, isquemia cerebral, accidente cerebrovascular, trombosis o retención de líquidos son también contemplados. Reivindicación 1: Un compuesto de fórmula (1), donde: uno de R1 y R2 es H y el otro es H, NR5R6, alcoxi C1-6, hidroxi, o halo; donde cada uno de R5 y R6 es independientemente H o alquilo C1-3; R3 es cloro; R45 es cloro, flúor, metoxi o metilo; o un éster C1-6, amida C1-6 o di(alquil C1-6)amida farmacéuticamente aceptable o su sal.
ARP040102087A 2003-06-17 2004-06-16 Espirobenzazepinas sustituidas utiles como antagonistas de los receptores de vasopresina AR044782A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47937803P 2003-06-17 2003-06-17

Publications (1)

Publication Number Publication Date
AR044782A1 true AR044782A1 (es) 2005-10-05

Family

ID=34465052

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102087A AR044782A1 (es) 2003-06-17 2004-06-16 Espirobenzazepinas sustituidas utiles como antagonistas de los receptores de vasopresina

Country Status (30)

Country Link
US (2) US20040266752A1 (es)
EP (1) EP1633719B1 (es)
JP (1) JP5252614B2 (es)
KR (1) KR101086246B1 (es)
CN (1) CN100467454C (es)
AR (1) AR044782A1 (es)
AT (1) ATE444953T1 (es)
AU (1) AU2004281257C1 (es)
BR (1) BRPI0411598A (es)
CA (1) CA2529649C (es)
CL (1) CL2004001507A1 (es)
CR (1) CR8168A (es)
CY (1) CY1109585T1 (es)
DE (1) DE602004023501D1 (es)
DK (1) DK1633719T3 (es)
EA (1) EA011089B1 (es)
ES (1) ES2332724T3 (es)
HR (2) HRP20051006A2 (es)
IL (1) IL172630A (es)
ME (1) ME00320B (es)
NO (1) NO20060247L (es)
NZ (1) NZ544180A (es)
PL (1) PL1633719T3 (es)
PT (1) PT1633719E (es)
RS (1) RS20050930A (es)
SI (1) SI1633719T1 (es)
TW (1) TWI354555B (es)
UA (1) UA82236C2 (es)
WO (1) WO2005037795A2 (es)
ZA (1) ZA200600430B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516177A (ja) * 2003-06-17 2007-06-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法
CA2637838A1 (en) * 2006-01-20 2007-07-26 Janssen Pharmaceutica N.V. Novel solid forms of (4r)-1-¬4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl|-1,2,3,5-tetrahydro-spiro¬4h-1-benzazepine-4,1'-¬2|cyclopentene|-3'-carboxylic acid
CN101541806A (zh) 2006-09-22 2009-09-23 詹森药业有限公司 用作血管升压素拮抗剂的螺环苯并氮杂
JP2010504352A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
JP2011503085A (ja) * 2007-11-07 2011-01-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アンギオテンシン変換酵素阻害剤及びバソプレッシン受容体拮抗薬を含む複合治療
US20150238502A1 (en) 2012-10-18 2015-08-27 University Of South Florida Compositions and Methods for Treating Stroke
RU2642783C2 (ru) 2012-12-26 2018-01-26 Санва Кагаку Кенкюсо Ко., Лтд. Новое производное бензоазепина и его медицинское применение

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
ES2089033T3 (es) 1989-10-20 1996-10-01 Otsuka Pharma Co Ltd Compuestos benzoheterociclicos.
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
CA2143117A1 (en) * 1992-10-07 1994-04-14 Ben E. Evans Tocolytic oxytocin receptor antagonists
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
PT758895E (pt) * 1994-04-22 2000-05-31 Univ Kingston Formas de dosagem sublingual contendo apomorfina para uso no tratamento da disfuncao erectil
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP3282494B2 (ja) * 1995-05-16 2002-05-13 富士ゼロックス株式会社 画像定着装置
US5753715A (en) 1995-06-02 1998-05-19 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
US5726723A (en) * 1996-01-31 1998-03-10 Technology Research International Corporation Sub-twisted nematic liquid crystal display
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
ATE305454T1 (de) * 2000-07-05 2005-10-15 Ortho Mcneil Pharm Inc Nichtpeptidische substituierte spirobenzoazepine als vasopressin antagonisten
JP2007516177A (ja) 2003-06-17 2007-06-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法

Also Published As

Publication number Publication date
AU2004281257B2 (en) 2010-02-04
EP1633719A2 (en) 2006-03-15
TW200515911A (en) 2005-05-16
HRP20090606T1 (hr) 2010-01-31
JP5252614B2 (ja) 2013-07-31
PL1633719T3 (pl) 2010-03-31
EA200501831A1 (ru) 2006-06-30
WO2005037795A2 (en) 2005-04-28
RS20050930A (en) 2008-04-04
US20040266752A1 (en) 2004-12-30
CR8168A (es) 2008-09-10
CA2529649A1 (en) 2005-04-28
ES2332724T3 (es) 2010-02-11
AU2004281257A1 (en) 2005-04-28
ZA200600430B (en) 2009-08-26
CY1109585T1 (el) 2014-08-13
IL172630A0 (en) 2006-04-10
CN1835925A (zh) 2006-09-20
EA011089B1 (ru) 2008-12-30
DE602004023501D1 (de) 2009-11-19
ATE444953T1 (de) 2009-10-15
TWI354555B (en) 2011-12-21
JP2007521272A (ja) 2007-08-02
PT1633719E (pt) 2009-11-11
US7687494B2 (en) 2010-03-30
KR101086246B1 (ko) 2011-11-23
US20070179128A1 (en) 2007-08-02
NZ544180A (en) 2009-01-31
CN100467454C (zh) 2009-03-11
MEP49108A (en) 2011-02-10
BRPI0411598A (pt) 2006-08-29
CL2004001507A1 (es) 2005-05-27
DK1633719T3 (da) 2010-01-04
UA82236C2 (en) 2008-03-25
IL172630A (en) 2011-10-31
EP1633719B1 (en) 2009-10-07
KR20060023157A (ko) 2006-03-13
WO2005037795A3 (en) 2005-07-28
SI1633719T1 (sl) 2010-01-29
ME00320B (me) 2011-05-10
CA2529649C (en) 2012-01-31
AU2004281257C1 (en) 2010-07-01
NO20060247L (no) 2006-03-13
HRP20051006A2 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
PE20221336A1 (es) Compuestos triciclicos sustituidos
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
AR065622A1 (es) Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
AR040773A1 (es) Pirazoles utiles como inhibidores de gsk-3
PE20060878A1 (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
AR080927A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas del receptor de v1a y un proceso para su obtencion
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
AR051920A1 (es) Derivados de quinazolinona como inhibidores del parp, un procedimiento de preparacion, composicion farmaceutica y proceso de preparacion de esta
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
AR074676A1 (es) Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa.
AR069480A1 (es) Derivados de 2-amino-pirimidina
AR044782A1 (es) Espirobenzazepinas sustituidas utiles como antagonistas de los receptores de vasopresina
AR074409A1 (es) Derivados de arilciclohexileteres de 5,6-dihidro-4h-2,3,5,10-b-tetraaza-benzo[e]azuleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en disfunciones sexuales y trastornos del snc, entre otras patologias.
AR046085A1 (es) Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico
CY1112270T1 (el) Σπειρο βενζαζεπινες χρησιμες ως ανταγωνιστες αγγειοπιεσινης
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
AR060904A1 (es) Derivados de 3,4-dihidro-2h-benzo [1,4] oxazina y tiazina como inhibidores de cetp

Legal Events

Date Code Title Description
FA Abandonment or withdrawal